Based on the analysis of STAAR Surgical's profitability, liquidity, and operating efficiency, STAAR Surgical is performing exceptionally good at this time. It has a great probability to report excellent financial results in December. At present, STAAR Surgical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 37.6 M, whereas Net Debt is projected to grow to (139.8 M). Key indicators impacting STAAR Surgical's financial strength include:
The essential information of the day-to-day investment outlook for STAAR Surgical includes many different criteria found on its balance sheet. An individual investor should monitor STAAR Surgical's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in STAAR Surgical.
Net Income
22.41 Million
STAAR
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Change To Inventory
Change To Account Receivables
Stock Based Compensation
Other Cashflows From Investing Activities
Total Cashflows From Investing Activities
Change To Liabilities
Change Receivables
Net Borrowings
Exchange Rate Changes
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Investments
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Accounts Payable
Common Stock
Intangible Assets
Common Stock Total Equity
Good Will
Other Liab
Current Deferred Revenue
Other Assets
Property Plant Equipment
Short Term Investments
Long Term Debt
Net Tangible Assets
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Capital Lease Obligations
Deferred Long Term Liab
Non Current Liabilities Other
Deferred Long Term Asset Charges
Short Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Selling General Administrative
Selling And Marketing Expenses
Minority Interest
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past STAAR Surgical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of STAAR Surgical's financial statements are interrelated, with each one affecting the others. For example, an increase in STAAR Surgical's assets may result in an increase in income on the income statement.
Please note, the presentation of STAAR Surgical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, STAAR Surgical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of STAAR Surgical's management manipulating its earnings.
STAAR Surgical Stock Summary
STAAR Surgical competes with ResMed, West Pharmaceutical, ICU Medical, Merit Medical, and Microbot Medical. STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Staar Surgical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 692 people.
Comparative valuation techniques use various fundamental indicators to help in determining STAAR Surgical's current stock value. Our valuation model uses many indicators to compare STAAR Surgical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across STAAR Surgical competition to find correlations between indicators driving STAAR Surgical's intrinsic value. More Info.
STAAR Surgical is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for STAAR Surgical is roughly 1.59 . At present, STAAR Surgical's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the STAAR Surgical's earnings, one of the primary drivers of an investment's value.
STAAR Surgical's Earnings Breakdown by Geography
STAAR Surgical Systematic Risk
STAAR Surgical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. STAAR Surgical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on STAAR Surgical correlated with the market. If Beta is less than 0 STAAR Surgical generally moves in the opposite direction as compared to the market. If STAAR Surgical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one STAAR Surgical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of STAAR Surgical is generally in the same direction as the market. If Beta > 1 STAAR Surgical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in STAAR Surgical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various STAAR Surgical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of STAAR Surgical growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.55
At present, STAAR Surgical's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
STAAR Surgical November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of STAAR Surgical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of STAAR Surgical. We use our internally-developed statistical techniques to arrive at the intrinsic value of STAAR Surgical based on widely used predictive technical indicators. In general, we focus on analyzing STAAR Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build STAAR Surgical's daily price indicators and compare them against related drivers.
When running STAAR Surgical's price analysis, check to measure STAAR Surgical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy STAAR Surgical is operating at the current time. Most of STAAR Surgical's value examination focuses on studying past and present price action to predict the probability of STAAR Surgical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move STAAR Surgical's price. Additionally, you may evaluate how the addition of STAAR Surgical to your portfolios can decrease your overall portfolio volatility.